Gå direkte til indholdet

Onkologi

Anæmibehandling

Erytropoiese-stimulerende lægemidler

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (åbner nyt vindue)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kilde‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indekseret‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (åbner nyt vindue)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (åbner nyt vindue)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Kilde‎: Acta Haematol 2007;117(3):162-7.

Indekseret‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (åbner nyt vindue)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (åbner nyt vindue)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Kilde‎: Am J Hematol 2013;88(12):990-6.

Indekseret‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (åbner nyt vindue)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (åbner nyt vindue)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Kilde‎: J Clin Oncol 2011;29(28):3791-7.

Indekseret‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (åbner nyt vindue)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (åbner nyt vindue)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Kilde‎: Cancer 2012;118(3):848-55.

Indekseret‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (åbner nyt vindue)

Management of anemia in cancer patients. (åbner nyt vindue)

Calabrich A, Katz A.

Kilde‎: Future Oncol 2011;7(4):507-17.

Indekseret‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (åbner nyt vindue)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (åbner nyt vindue)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Kilde‎: BJU Int 2011;108(10):1582-7.

Indekseret‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (åbner nyt vindue)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (åbner nyt vindue)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Kilde‎: J Clin Oncol 2010;28(13):2239-45.

Indekseret‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (åbner nyt vindue)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (åbner nyt vindue)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Kilde‎: Br J Cancer 2011;105(9):1267-72.

Indekseret‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (åbner nyt vindue)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (åbner nyt vindue)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Kilde‎: J Intern Med 2017;281(3):284-99.

Indekseret‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (åbner nyt vindue)

How I treat cancer-associated anemia. (åbner nyt vindue)

Gilreath JA, Rodgers GM

Kilde‎: Blood 2020;136(7):801-13.

Indekseret‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (åbner nyt vindue)

Update on safety of ESAs in cancer-induced anemia. (åbner nyt vindue)

Glaspy J.

Kilde‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Indekseret‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (åbner nyt vindue)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (åbner nyt vindue)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kilde‎: Eur J Haematol. 2023 110(4):354-61.

Indekseret‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (åbner nyt vindue)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (åbner nyt vindue)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Kilde‎: Int J Hematol 2015;102(4):401-12.

Indekseret‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (åbner nyt vindue)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (åbner nyt vindue)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Kilde‎: Cancer 2013;119(1):107-14.

Indekseret‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (åbner nyt vindue)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (åbner nyt vindue)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Kilde‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indekseret‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (åbner nyt vindue)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (åbner nyt vindue)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Kilde‎: Cancer Sci 2013;104(4):481-5.

Indekseret‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (åbner nyt vindue)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (åbner nyt vindue)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Kilde‎: Br J Haematol 2019;184(2):134-60.

Indekseret‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (åbner nyt vindue)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (åbner nyt vindue)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Kilde‎: Support Care Cancer 2012;20(1):159-65.

Indekseret‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (åbner nyt vindue)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (åbner nyt vindue)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Kilde‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indekseret‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (åbner nyt vindue)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (åbner nyt vindue)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Kilde‎: Oncologist 2010;15(9):935-43.

Indekseret‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (åbner nyt vindue)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (åbner nyt vindue)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Kilde‎: Lung Cancer 2012;76(3):478-85.

Indekseret‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (åbner nyt vindue)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (åbner nyt vindue)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Kilde‎: Eur J Haematol 2016;97(1):33-8.

Indekseret‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (åbner nyt vindue)

Intravenøs jern

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (åbner nyt vindue)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kilde‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indekseret‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (åbner nyt vindue)

Intravenous iron in oncology. (åbner nyt vindue)

Auerbach M, Ballard H.

Kilde‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indekseret‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (åbner nyt vindue)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (åbner nyt vindue)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Kilde‎: Int J Colorectal Dis 2016;31(3):543-51.

Indekseret‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (åbner nyt vindue)

How I treat cancer-associated anemia. (åbner nyt vindue)

Gilreath JA, Rodgers GM

Kilde‎: Blood 2020;136(7):801-13.

Indekseret‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (åbner nyt vindue)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (åbner nyt vindue)

Gilreath JA, Stenehjem DD, Rodgers GM.

Kilde‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indekseret‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (åbner nyt vindue)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (åbner nyt vindue)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kilde‎: Eur J Haematol. 2023 110(4):354-61.

Indekseret‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (åbner nyt vindue)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (åbner nyt vindue)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Kilde‎: Curr Oncol. 2023 24;30(9):7836-51.

Indekseret‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (åbner nyt vindue)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (åbner nyt vindue)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Kilde‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indekseret‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (åbner nyt vindue)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (åbner nyt vindue)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Kilde‎: World J Gastroenterol 2014;20(8):1972-85.

Indekseret‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (åbner nyt vindue)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (åbner nyt vindue)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Kilde‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indekseret‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (åbner nyt vindue)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (åbner nyt vindue)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Kilde‎: J Clin Oncol 2008;26(10):1619-25.

Indekseret‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (åbner nyt vindue)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (åbner nyt vindue)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Kilde‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indekseret‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (åbner nyt vindue)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (åbner nyt vindue)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Kilde‎: Ann Oncol 2013;24(2):475-82.

Indekseret‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (åbner nyt vindue)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (åbner nyt vindue)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Kilde‎: Am J Hematol 2024;99(7):1338-48.

Indekseret‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (åbner nyt vindue)

ONKOLOGI
Anæmibehandling
Dansk
Anæmibehandling
https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Kontaktudvalg til Hospitaler (KUH)

Ret henvendelse til lokale kontaktpersoner der uden betaling hjælper læger som behandler patienter der er Jehovas Vidner.

Kontakt

Informationsmateriale til sundhedspersonale

Indbefatter følgende emner: Kliniske strategier for behandling af hæmoragi og anæmi uden blodtransfusion, Jehovas Vidners religiøse og etiske holdning til lægebehandling og den hjælp Vidnerne tilbyder læger gennem deres globale netværk Kontaktudvalg til Hospitaler.

Se materiale der kan downloades

Videoer

Behandlingsmuligheder læger kan gøre brug af når de skal behandle Jehovas Vidner, såvel som lægefaglige og etiske overvejelser.

Se videoer